FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

ImmunityBio Inc. (NASDAQ:IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related to its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer (NMIBC).The stock is trading higher with a session volume of 178.91 million versus the average volume of 15.9 million, as per data from Benzinga Pro.The company said the FDA provided feedback during disc ...